Table 3.
Signaling pathway enrichment analysis of DEGs function in ovarian cancer
| Pathway | Name | Count | p-value | Genes |
|---|---|---|---|---|
| Up-regulated DEG | ||||
| R-HSA-380108 | Chemokine receptors bind chemokines | 6 | 5.26E-04 | CCL11, CXCL13, CXCL9, ACKR2, CXCL11, CXCL10 |
| R-HSA-418594 | G alpha (i) signaling events | 9 | 0.00675 | GNGT1, PTGER3, CXCL13, NPW, CXCL9, GPR17, PDYN, CXCL11, CXCL10 |
| KEGG: hsa04062 | Chemokine signaling pathway | 7 | 0.01032 | CCL11, GNGT1, CXCL14, CXCL13, CXCL9, CXCL11, CXCL10 |
| KEGG: hsa04060 | Cytokine-cytokine receptor interaction | 7 | 0.02668 | CCL11, CXCL14, CXCL13, CXCL9, TNFRSF17, CXCL11, CXCL10 |
| R-HSA-68877 | Mitotic Prometaphase | 5 | 0.03419 | SPC25, CDCA8, NUF2, CENPE, SKA1 |
| R-HSA-2500257 | Resolution of Sister Chromatid Cohesion | 5 | 0.04855 | SPC25, CDCA8, NUF2, CENPE, SKA1 |
| Down-regulated DEG | ||||
| R-HSA-499943 | Interconversion of nucleotide di- and triphosphates | 3 | 0.01646 | AK7, AK9, AK8 |